Replimune Group, Inc. - Common Stock (REPL)

Replimune Group Inc is a biotechnology company focused on developing innovative therapies for cancer treatment using its proprietary oncolytic virus platform

By harnessing genetically engineered viruses that selectively target and destroy cancer cells while stimulating the body’s immune system, Replimune aims to revolutionize the approach to cancer care. The company's research and development efforts are centered on creating novel therapeutic options that can potentially provide more effective and less toxic alternatives to traditional cancer treatments. Through their commitment to scientific advancement, Replimune is poised to make significant contributions to the field of oncology.